ASH 2024: Focus on MDS
Review the latest research and clinical guidance in myelodysplastic syndromes presented at the 2024 ASH Annual Meeting.
Advertisement
Advertisement
Nicole Grieselhuber, MD, PhD on results of SEA-CD70 treatment in patients with high-risk MDS.
An expert panel delves into new data regarding the long-term efficacy of luspatercept in MDS.
An expert MDS panel discusses patient reported outcomes, transfusion dependence, and time toxicity.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
An expert speaks on site at ASH 2024 about the health-related quality of life data from the phase 3 COMMANDS trial.
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
A discussion on the post hoc analysis on quality of life from the COMMANDS trial.
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
How to address ESA failure or ineligibility in patients with MDS...
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
An ongoing phase 1 study is evaluating the safety and efficacy of danvatirsen through two substudies.
HMA plus venetoclax may achieve higher response rates and improve event-free survival in high-risk MDS.
In a murine mitochondrial succinate dehydrogenase knockdown model of low-risk MDS luspatercept alleviated anemia.
New WHO and ICC 022 guidelines propose lowering the threshold for diagnosis of CMML.
High-risk MDS is associated with poor outcomes, making the assessment of treatment response critical.
Hypomethylating agents, such as azacitidine, are the standard-of-care treatment for MDS.
The design of a phase 3 trial of elritercept for transfusion-dependent anemia in lower-risk MDS was presented at ASH 2024.
Increasing evidence suggests a connection between acquired somatic mutations and inflammatory processes in myeloid neoplasms.
The clinical activity of vibecotamab in low-blast, high-risk myeloid neoplasms has been demonstrated in a phase II study.
What potential does ASTX727 have in MDS and AML treatment?
Somatic IDH1 mutations are present in approximately 3% of patients with MDS and are associated with poor prognosis.
New research is offering new hope for these challenging case of MDS and sAML.
Ivosidenib is a promising oral therapy for patients with IDH1-mutated MDS.
Overall survival is improved in patients with SF3B1del5q-mutated MDS when lenalidomide is sequenced before luspatercept.
Findings from a phase II trial study of patients with MDS highlight the clinical benefits and safety profile of enasidenib.
Ceralasertib is a novel oral ataxia telangiectasia and Rad3-related inhibitor for patients with myelodysplastic syndromes.
The presence of genetic mutations and specific cytopenias emerged as key predictors of progression in MDS.
The phase 3 COMMANDS trial results underscore the potential longer-term clinical benefits of luspatercept in lower-risk MDS.
Phase 2 results of AZA-VEN in acute myeloid leukemia shows an efficacy benefit.
New findings underscore the potential of single-cell analyses in the unbiased unraveling of disease mechanisms in MDS.
Results from the phase 1 Combala study show the benefit of luspatercept and erythropoiesis-stimulating agents in MDS.
The phase 3 EPO-PRETAR trial demonstrates importance of early administration of ESAs in patients with MDS and anemia.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.